Drug-drug interaction between isavuconazole and tacrolimus: a case report indicating the need for tacrolimus drug-level monitoring

被引:18
|
作者
Kim, T. [1 ]
Jancel, T. [2 ]
Kumar, P. [1 ]
Freeman, A. F. [3 ]
机构
[1] NIH, Ctr Clin, Dept Pharm, Bethesda, MD 20892 USA
[2] US FDA, Off Safety & Epidemiol, Silver Spring, MD USA
[3] NIAID, Lab Clin Infect Dis, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
drug-drug interaction; new antifungal agent; therapeutic drug monitoring;
D O I
10.1111/jcpt.12308
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and objectiveDespite the known significant drug-drug interaction between isavuconazole and tacrolimus, there are no recommendations on dose adjustment when these drugs are given concomitantly. We report on a patient with amediastinal Aspergillus fumigatus infection resistant to posaconazole and describe how she was successfully managed with tacrolimus therapeutic drug-level monitoring. Case summaryOur patient presented with a mediastial Aspergillus fumigatus infection, 2years after lung transplantation. A.fumigatus was resistant to posaconazole, and the patient had intolerance to voriconazole shown by elevated transaminases. The patient was given isavuconazole with drug-level monitoring. She was managed successfully with no adverse events. Tacrolimus concentration continued to increase after more than 2weeks of therapy and required a further reduction to 72% of the usual dose to maintain the target concentrations over a 8-week period. What is new and conclusionWhen isavuconazole is given to patients on tacrolimus, the dose of the latter will need considerable reduction. We would suggest an initial 50% reduction and recommend close weekly monitoring of tacrolimus concentration. Further dose decreases of 25-50% may be required.
引用
收藏
页码:609 / 611
页数:3
相关论文
共 50 条
  • [41] Response to Comment on "Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin"
    Sindelar, Morganne
    McCabe, Daniel
    Carroll, Elisabeth
    JOURNAL OF MEDICAL TOXICOLOGY, 2023, 19 (03) : 309 - 309
  • [42] Drug-Drug Interaction in a Kidney Transplant Recipient Receiving HIV Salvage Therapy and Tacrolimus
    Mertz, Dominik
    Battegay, Manuel
    Marzolini, Catia
    Mayr, Michael
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (01) : E1 - E4
  • [44] Case report: Drug-drug interaction between alectinib and apixaban in NSCLC
    Gulikers, J. L.
    Slikkerveer, M.
    Winckers, K.
    Hendriks, L. E. L.
    Dursun, S.
    Croes, S.
    van Geel, R. M. J. M.
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2022, 7
  • [45] Drug Interaction Between Tacrolimus and Carbamazepine in a Japanese Heart Transplant Recipient: A Case Report
    Wada, Kyoichi
    Takada, Mitsutaka
    Sakai, Mika
    Ochi, Hiroyuki
    Kotake, Takeshi
    Okada, Hiroshi
    Morishita, Hideki
    Oda, Noboru
    Mano, Akiko
    Kato, Tomoko S.
    Komamura, Kazuo
    Nakatani, Takeshi
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (04): : 409 - 411
  • [46] Pharmacokinetic drug-drug interaction between olaparib and apixaban: a case report
    Berge, M.
    Giraud, J. S.
    De Percin, S.
    Puszkiel, A.
    Thomas-Schoemann, A.
    Blanchet, B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (05) : 519 - 521
  • [47] Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults
    Groll, Andreas H.
    Desai, Amit
    Han, David
    Howieson, Corrie
    Kato, Kota
    Akhtar, Shahzad
    Kowalski, Donna
    Lademacher, Christopher
    Lewis, William
    Pearlman, Helene
    Mandarino, Debra
    Yamazaki, Takao
    Townsend, Robert
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2017, 6 (01): : 76 - 85
  • [49] Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection
    Chen, Ying
    Wan, Wenbin
    Yao, Xiaoying
    Guan, Yangtai
    JOURNAL OF NEUROIMMUNOLOGY, 2023, 385